Market Research

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA [Enzyme Linked Immunosorbent Assay], Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Foreca

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 203 Pages Transparency Market Research Pvt. Ltd. May, 2023 TNPR18030418
Best Price Guarantee
Price from $5,795
Length 203 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date May, 2023
SKU TNPR18030418

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA [Enzyme Linked Immunosorbent Assay], Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Fecal Calprotectin Test Market – Scope of Report


TMR’s report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report
  • What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
  • What are the opportunities in the global Fecal Calprotectin Test market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market – Research Objectives and Research Approach


The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fecal Calprotectin Test Market
4. Market Overview
4.1. Introduction
4.1.1. Patient Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancement
5.2. Diseases Epidemiology
5.3. Regulatory Scenario
5.4. Pricing Analysis
5.5. COVID-19 Impact Analysis
6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Patient Type, 2017-2031
6.3.1. Adult
6.3.2. Pediatric
6.4. Market Attractiveness Analysis, by Patient Type
7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Assay Type, 2017-2031
7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
7.3.2. Enzyme Fluoroimmunoassay
7.3.3. Quantitative Immune-chromatography
7.4. Market Attractiveness Analysis, by Assay Type
8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2017-2031
8.3.1. Inflammatory Bowel Disease
8.3.2. Colorectal Cancer
8.3.3. Celiac Disease
8.4. Market Attractiveness Analysis, by Indication
9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Academic & Research Institutes
9.4. Market Attractiveness Analysis, by End-user
10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Fecal Calprotectin Test Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Patient Type, 2017-2031
11.2.1. Adult
11.2.2. Pediatric
11.3. Market Value Forecast, by Assay Type, 2017-2031
11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
11.3.2. Enzyme Fluoroimmunoassay
11.3.3. Quantitative Immune-chromatography
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Inflammatory Bowel Disease
11.4.2. Colorectal Cancer
11.4.3. Celiac Disease
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Academic & Research Institutes
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Patient Type
11.7.2. By Assay Type
11.7.3. By Indication
11.7.4. By End-user
11.7.5. By Country
12. Europe Fecal Calprotectin Test Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Patient Type, 2017-2031
12.2.1. Adult
12.2.2. Pediatric
12.3. Market Value Forecast, by Assay Type, 2017-2031
12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
12.3.2. Enzyme Fluoroimmunoassay
12.3.3. Quantitative Immune-chromatography
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Inflammatory Bowel Disease
12.4.2. Colorectal Cancer
12.4.3. Celiac Disease
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Laboratories
12.5.3. Academic & Research Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Patient Type
12.7.2. By Assay Type
12.7.3. By Indication
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Patient Type, 2017-2031
13.2.1. Adult
13.2.2. Pediatric
13.3. Market Value Forecast, by Assay Type, 2017-2031
13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
13.3.2. Enzyme Fluoroimmunoassay
13.3.3. Quantitative Immune-chromatography
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Inflammatory Bowel Disease
13.4.2. Colorectal Cancer
13.4.3. Celiac Disease
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Laboratories
13.5.3. Academic & Research Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Patient Type
13.7.2. By Assay Type
13.7.3. By Indication
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Fecal Calprotectin Test Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Patient Type, 2017-2031
14.2.1. Adult
14.2.2. Pediatric
14.3. Market Value Forecast, by Assay Type, 2017-2031
14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
14.3.2. Enzyme Fluoroimmunoassay
14.3.3. Quantitative Immune-chromatography
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Inflammatory Bowel Disease
14.4.2. Colorectal Cancer
14.4.3. Celiac Disease
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Laboratories
14.5.3. Academic & Research Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Patient Type
14.7.2. By Assay Type
14.7.3. By Indication
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Patient Type, 2017-2031
15.2.1. Adult
15.2.2. Pediatric
15.3. Market Value Forecast, by Assay Type, 2017-2031
15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
15.3.2. Enzyme Fluoroimmunoassay
15.3.3. Quantitative Immune-chromatography
15.4. Market Value Forecast, by Indication, 2017-2031
15.4.1. Inflammatory Bowel Disease
15.4.2. Colorectal Cancer
15.4.3. Celiac Disease
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Laboratories
15.5.3. Academic & Research Institutes
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Patient Type
15.7.2. By Assay Type
15.7.3. By Indication
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competitive Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Abbexa
16.3.1.1. Company Overview
16.3.1.2. Drug Class Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Financial Overview
16.3.1.5. Strategic Overview
16.3.2. ALPCO
16.3.2.1. Company Overview
16.3.2.2. Drug Class Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Financial Overview
16.3.2.5. Strategic Overview
16.3.3. Alpha Laboratories
16.3.3.1. Company Overview
16.3.3.2. Drug Class Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Financial Overview
16.3.3.5. Strategic Overview
16.3.4. Biomerica
16.3.4.1. Company Overview
16.3.4.2. Drug Class Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Financial Overview
16.3.4.5. Strategic Overview
16.3.5. BÜHLMANN Laboratories AG
16.3.5.1. Company Overview
16.3.5.2. Drug Class Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Financial Overview
16.3.5.5. Strategic Overview
16.3.6. DRG Instruments GmbH
16.3.6.1. Company Overview
16.3.6.2. Drug Class Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Financial Overview
16.3.6.5. Strategic Overview
16.3.7. EagleBio
16.3.7.1. Company Overview
16.3.7.2. Drug Class Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Financial Overview
16.3.7.5. Strategic Overview
16.3.8. Epitope Diagnostics, Inc.
16.3.8.1. Company Overview
16.3.8.2. Drug Class Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Financial Overview
16.3.8.5. Strategic Overview
16.3.9. OPERON, S.A.
16.3.9.1. Company Overview
16.3.9.2. Drug Class Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Financial Overview
16.3.9.5. Strategic Overview
16.3.10. R-Biopharm AG
16.3.10.1. Company Overview
16.3.10.2. Drug Class Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Financial Overview
16.3.10.5. Strategic Overview
16.3.11. Svar Life Science
16.3.11.1. Company Overview
16.3.11.2. Drug Class Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Financial Overview
16.3.11.5. Strategic Overview
16.3.12. Thermo Fisher Scientific, Inc.
16.3.12.1. Company Overview
16.3.12.2. Drug Class Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Financial Overview
16.3.12.5. Strategic Overview
16.3.13. Werfen
16.3.13.1. Company Overview
16.3.13.2. Drug Class Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Financial Overview
16.3.13.5. Strategic Overview
16.3.14. SENTINEL CH. SpA
16.3.14.1. Company Overview
16.3.14.2. Drug Class Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Financial Overview
16.3.14.5. Strategic Overview
16.3.15. Diazyme Laboratories, Inc.
16.3.15.1. Company Overview
16.3.15.2. Drug Class Portfolio
16.3.15.3. SWOT Analysis
16.3.15.4. Financial Overview
16.3.15.5. Strategic Overview
16.3.16. DiAgam
16.3.16.1. Company Overview
16.3.16.2. Drug Class Portfolio
16.3.16.3. SWOT Analysis
16.3.16.4. Financial Overview
16.3.16.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings